Caris Life Sciences

Caris Life Sciences recently published a study in JAMA Network Open, titled “An AI Approach to Differentiating Lung Squamous Cell Carcinoma From Metastases of Other Origins,” which builds on the body of evidence showing the superiority of Caris’ proprietary and world-leading GPSai® algorithm over traditional diagnostic procedures in correctly diagnosing cancer types. Learn more: ow.ly/5c2Y50YwBTS

Join Caris at the USCAP Annual Meeting in San Antonio, Texas. Visit our team at booth 512 to learn how our comprehensive molecular profiling services are helping advance precision medicine and supporting pathologists with deeper insights for clinical decision making. Learn more and schedule a meeting with our team during the meeting: bit.ly/4uztffB

Caris Life Sciences announced the addition of a platinum resistance AI signature to the growing portfolio of Caris AI Insights™. This new signature is designed to predict early platinum resistance in patients with high-grade serous ovarian cancer (HGSOC) and provides clinicians with unprecedented molecular insight into how long a patient may benefit from first-line platinum-based chemotherapy. Learn more: ow.ly/PZWb50YtNkU

Join pathology leaders and industry collaborators for a Caris Research Collaborators Networking Reception on Monday, March 23, 2026. The evening includes networking and a short panel discussion on real world, high impact pathology research conducted with Caris Precision Oncology Alliance institutions and biopharma partners. Learn more and register: carislifesciences.com/poa-uscap-2026/

In recognition of Colorectal Cancer Awareness Month, we highlight a recent study published in the journal Cancer Cell showing that tumor-infiltrating clonal hematopoiesis (TI-CH) isn’t always tied to poor prognosis. TET2 TI-CH was linked to better immunotherapy outcomes in large CRC (n=25,064) & NSCLC (n=35,316) cohorts, highlighting the value of directly measuring CH. Learn more about the research: ow.ly/EivO50YrWTk

Caris Life Sciences and collaborators from leading cancer centers will collectively present five studies at the 2026 United States and Canadian Academy of Pathology (@TheUSCAP) Annual Meeting in San Antonio, Texas, to be held March 21–26, 2026. Learn more: ow.ly/rejW50Ys7co

Understanding TET2‑mutant clonal hematopoiesis can help refine clinical decision-making in precision oncology. Join Milan Radovich, PhD, and Shelley Herbrich, PhD, MS, as they discuss data from a TET2‑mutant clonal hematopoiesis study and examine its prevalence, biological context and potential clinical implications. Reserve your seat and join the conversation: ow.ly/8imc50YryCx

Today Caris Life Sciences announced the launch of a novel, proprietary Caris AI Insights™ signature for pancreatic cancer included in the Caris Molecular Tumor Board Report, available upon request with no additional tissue sampling required when ordering MI Cancer Seek®. Caris advances precision oncology by using AI to analyze data from comprehensive real-world datasets, including its CodeAI™ platform, comprised of over 550,000 patients. By integrating sequencing and clinical data, Caris develops next-generation multimodal models that generate deeper biological insights, accelerate biomarker discovery, and support more personalized cancer treatment decisions. Learn more: ow.ly/Ema150Yqzsr

A recent study from the American Cancer Society (@AmericanCancer) shows colorectal cancer is now the leading cause of cancer-related deaths in people under 50 in the United States. Caris supports informed treatment decisions in metastatic CRC with Caris FOLFIRSTai, an AI-driven molecular predictor of chemotherapy efficacy. Learn more: ow.ly/Q36J50Yo7Br

What genomic signals might predict response to belzutifan in renal cell carcinoma? Dr. @yuweichenMD will share data from a study of 240 patients, highlighting PI3K/AKT/mTOR and DDR alterations in responders and chromatin remodeling in non-responders. ow.ly/yyWA50YhmEp #GU26

Caris Life Sciences completed the interim readout of Achieve 1, the study supporting the upcoming launch of Caris Detect™, its multi-cancer early detection (MCED) test. Learn more: ow.ly/m5JC50YmKsZ

Caris Life Sciences reported financial results 2025 Q4 and full year, which included full year revenue growth of 97% driven by strong performance in molecular profiling services. The company expects full year 2026 revenue to be in the range of $1.0 billion to $1.02 billion Learn more: ow.ly/3ccs50YmEQQ

At Caris, we follow the “Mom Rule”: Treat every patient like they’re your own mom. Sanjeev did just that and it helped save his mother. Read their story: bit.ly/44CJSL0

Caris Life Sciences announced a new breast cancer signature included in the Caris Molecular Tumor Board Report. Caris recently added the breast cancer signature for capecitabine to the Caris AI Insights section of the report. Learn more: ow.ly/PKvt50YkN2K

Caris Life Sciences will participate in the TD Cowen 46th Annual Health Care Conference, which will be held March 2-4, 2026, in Boston, Massachusetts. Learn more: ow.ly/n2RQ50Yj7xz

Attending the American Society of Clinical Oncology (@ASCO) Genitourinary (GU) Cancers Symposium in San Francisco? Stop by Booth 73 to meet with our experts and learn what Caris has in store for the future of precision medicine. Learn more: ow.ly/bqiQ50YiRME

MI Cancer Seek® offers a different approach to profiling solid tumors using both WES & WTS technologies. FDA-approved for molecular profiling of solid tumors in adult & pediatric (ages 1-22) patients. Learn more & view important product info: bit.ly/4lyGNTR